(BME) BlackRock Health Sciences - Ratings and Ratios

BlackRock Health Sciences Trust (NYSE:BME) is a closed-end equity mutual fund established by BlackRock, Inc. and managed by BlackRock Advisors, LLC. The fund focuses on investing in U.S. public equity markets, targeting companies in the health sciences sector, including those involved in medical, dental, optical, pharmaceutical, and biotechnology products, supplies, equipment, or services. The fund employs a strategy that includes equity derivatives, with a particular emphasis on option writing. It benchmarks its performance against the Russell 3000 Healthcare Index. Established on March 31, 2005, the fund is domiciled in the United States and provides investors with exposure to a diversified portfolio of health sciences-related assets.

From a technical perspective, BME is trading at $40.00 with a 20-day SMA of $40.36, indicating slight downside momentum. The 50-day SMA of $39.17 and 200-day SMA of $39.31 suggest a neutral to slightly bullish longer-term trend. The ATR of 0.47 reflects low volatility, suggesting stable price movements. Average 20-day volume of 32,759 shares indicates moderate liquidity.

Fundamentally, BME has a market cap of $536.72 million, with a P/E ratio of 10.30, indicating reasonable valuation relative to earnings. The P/B ratio of 0.87 suggests the fund is trading below its book value, potentially offering value. The P/S ratio of 67.17 is elevated, reflecting a premium for exposure to the health sciences sector. The Return on Equity (RoE) of 13.30% highlights efficient profitability.